Simultaneous microdetermination of bosentan, ambrisentan, sildenafil, and tadalafil in plasma using liquid chromatography/tandem mass spectrometry for pediatric patients with pulmonary arterial hypertension

• A simultaneous determination method for 4 PAH drugs was developed.
• Bosentan, ambrisentan, sildenafil and tadalafil were analyzed by LC–MS/MS in 5 min.
• The developed method requires ultralow volume (50 μL) of plasma sample.
• The method was applied to determination of plasma samples of pediatric PAH patients.

A simultaneous, selective, sensitive, and rapid liquid chromatography/tandem mass spectrometry (LC–MS/MS) method was developed and validated for the quantification of bosentan, ambrisentan, sildenafil, and tadalafil in 50 μL of human blood plasma. Diluted plasma samples were extracted using a solid-phase extraction procedure with 2% formic acid and methanol. The four drugs were separated by high-performance liquid chromatography using a C18 column and an isocratic mobile phase running at a flow rate of 0.2 mL/min for 5 min. The drugs were detected by a tandem mass spectrometer with electrospray ionization using deuterated compounds as internal standards. Calibration curves were generated over the linear concentration range of 2–1000 ng/mL in plasma with a lower limit of quantification of 2 ng/mL for all compounds. Finally, this validated method was applied to a clinical pharmacokinetic study in pediatric patients with pulmonary arterial hypertension (PAH) following the oral administration of PAH drugs. These results indicate that this method is suitable for assessing the risk/benefit of combination therapy in the pediatric population and useful for therapeutic drug monitoring for PAH treatment.

Figure optionsDownload as PowerPoint slide